Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Expected to Earn Q3 2017 Earnings of $1.98 Per Share

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Investment analysts at SunTrust Banks upped their Q3 2017 earnings estimates for Jazz Pharmaceuticals PLC in a research report issued on Sunday. SunTrust Banks analyst J. Boris now expects that the specialty pharmaceutical company will post earnings per share of $1.98 for the quarter, up from their previous forecast of $1.95. SunTrust Banks also issued estimates for Jazz Pharmaceuticals PLC’s Q4 2017 earnings at $2.17 EPS, FY2018 earnings at $8.86 EPS, FY2019 earnings at $11.52 EPS, FY2020 earnings at $13.65 EPS and FY2021 earnings at $15.61 EPS.

A number of other analysts also recently commented on JAZZ. Cowen and Company reaffirmed an “outperform” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday. Deutsche Bank AG set a $175.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Wednesday. Royal Bank Of Canada reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday. Janney Montgomery Scott reissued a “buy” rating and issued a $192.00 target price (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday. Finally, Zacks Investment Research raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price target for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $183.26.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://sportsperspectives.com/2017/08/10/jazz-pharmaceuticals-plc-nasdaqjazz-expected-to-earn-q3-2017-earnings-of-1-98-per-share.html.

Jazz Pharmaceuticals PLC (JAZZ) opened at 142.90 on Wednesday. The firm has a market cap of $8.58 billion, a price-to-earnings ratio of 21.59 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The firm’s 50 day moving average price is $155.76 and its 200 day moving average price is $145.81.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the firm earned $2.67 EPS.

In related news, Director Rick E. Winningham sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $150.00, for a total value of $750,000.00. Following the transaction, the director now directly owns 10,391 shares of the company’s stock, valued at approximately $1,558,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $152.98, for a total value of $30,596.00. Following the completion of the transaction, the executive vice president now directly owns 22,623 shares in the company, valued at $3,460,866.54. The disclosure for this sale can be found here. Insiders sold a total of 10,600 shares of company stock worth $1,641,720 over the last ninety days. 4.30% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in JAZZ. Somerset Trust Co boosted its position in Jazz Pharmaceuticals PLC by 0.4% in the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock valued at $497,000 after buying an additional 14 shares during the period. Level Four Advisory Services LLC boosted its position in Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Level Four Advisory Services LLC now owns 2,729 shares of the specialty pharmaceutical company’s stock valued at $389,000 after buying an additional 23 shares during the period. World Asset Management Inc boosted its position in Jazz Pharmaceuticals PLC by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 27 shares during the period. Mn Services Vermogensbeheer B.V. boosted its position in Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock valued at $217,000 after buying an additional 44 shares during the period. Finally, Nomura Asset Management Co. Ltd. boosted its position in Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Nomura Asset Management Co. Ltd. now owns 6,550 shares of the specialty pharmaceutical company’s stock valued at $951,000 after buying an additional 50 shares during the period. 86.43% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply